If the patient is suffering from a bacterial infection that is resistant to the antibiotic being prescribed, the treatment will be ineffective, allowing the bacteria to continue to infect the patient. Furthermore, patients can have life-threatening side effects such as organ failure when severe bacterial infections that require second and third-line treatments are resistant to frontline antibiotics.

“Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019,” the Centers for Disease Control and Prevention (CDC) warns. “In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year.”

ResistantPath™ (Multiplex Antibiotic Resistance Gene RT-PCR Panel Test)

The CDC found that at least 30% of antibiotics prescribed in the US were unnecessary and, with that number likely growing due to increased antibiotic resistance, the measurements and improvements in prescribing antibiotics through antibiotic stewardship programs are a necessity to stopping this growing problem through precision medicine.

Microbial resistance genes appear due to the overprescribing and overuse of broad-spectrum antibiotics. Antibiotic stewardship is essential in correcting this healthcare crisis through data-driven results on resistant gene detection, pathogen load, and sensitivity. Therefore, our lab stays up to date with new data from antibiotic stewardship programs so our ResistantPath™ panel tests for the most current resistant genes.

Our ResistantPath™ panel test tests for seven (7) antibiotic-resistant genes that may be present:

  1. mecA, 2. mcr-1, 3. tetM, 4. tetS, 5. vanA, 6. vanB & 7. sul1

Certifications and Accreditations